Oncología médica
Especialidad
Hospital Arnau de Vilanova
Valencia, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Arnau de Vilanova (18)
2024
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328
-
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
ESMO Open, Vol. 9, Núm. 10
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
2021
-
Early imaging and molecular changes with neoadjuvant bevacizumab in stage ii/iii breast cancer
Cancers, Vol. 13, Núm. 14
-
First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
European Journal of Cancer, Vol. 159, pp. 174-181
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
2018
-
A risk-adapted approach to patients with stage i seminoma according to the status of rete testis: The fourth Spanish germ cell cancer group study
Oncology (Switzerland), Vol. 95, Núm. 1, pp. 8-12
2017
2016
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2014
-
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer
Oncology Research, Vol. 21, Núm. 4, pp. 181-191
-
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies
Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155
2013
-
SEOM clinical guidelines for the management of metastatic breast cancer 2013
Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1004-1010
2010
-
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
Lung Cancer, Vol. 68, Núm. 3, pp. 491-497
2006
-
The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer
Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3
2003
-
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil
Clinical Colorectal Cancer, Vol. 3, Núm. 3, pp. 174-179
-
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial
Journal of Clinical Oncology, Vol. 21, Núm. 17, pp. 3207-3213
-
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: A multicentre phase II study
Lung Cancer, Vol. 39, Núm. 2, pp. 201-207